Workflow
Centene(CNC)
icon
Search documents
Centene Corporation (CNC) Fell in Q3 As It Retracted Its 2025 Guidance
Yahoo Finance· 2026-01-05 12:15
Fund Performance - Artisan Mid Cap Value Fund's Investor Class fund ARTQX returned 0.97%, Advisor Class fund APDQX posted a return of 0.98%, and Institutional Class fund APHQX returned 0.97% in Q3 2025, compared to a 6.18% return for the Russell Midcap Value Index [1] Market Context - Equity markets continued to rally in Q3 2025 as investors overlooked tariff concerns, driven by strong corporate earnings, rising AI capital expenditures, and hopes for economic support from US fiscal policy and lower interest rates [1] Centene Corporation Overview - Centene Corporation (NYSE:CNC) is a healthcare enterprise that provides services to under-insured and uninsured families and commercial organizations, with a one-month return of 10.30% and a 52-week loss of 33.35% [2] - As of January 2, 2026, Centene's stock closed at $41.78 per share, with a market capitalization of $20.536 billion [2] Performance Analysis of Centene Corporation - The portfolio's stock selection was broadly negative across sectors in Q3 2025, with the healthcare sector being a significant source of underperformance, particularly due to Centene Corporation, Align Technology, and Baxter International [3] - Centene's shares declined after the company withdrew its 2025 guidance due to higher-than-expected market acuity on the ACA marketplaces and elevated Medicaid cost trends, compounded by a declining trend in Medicaid enrollment [3] - The end of the pandemic-era policy prohibiting disenrollment from Medicaid has led to millions losing coverage, and new work requirements from the Big Beautiful Bill (BBB) set to take effect on January 1, 2027, are expected to create additional headwinds for Medicaid enrollment [3] - Although Centene can reprice risk annually, the multitude of challenges it faces, including changes from the BBB, will likely delay recovery, prompting the fund to exit its position in Centene [3]
Centene Corporation: Why The Market Is Still On The Fence (NYSE:CNC)
Seeking Alpha· 2026-01-02 14:00
Core Viewpoint - Centene's stock appears to be in a balanced state, with no significant potential for a major increase or decrease in the near term for investors planning to hold the stock [1] Summary by Relevant Categories Company Analysis - Centene's stock is currently priced at a level that suggests stability, indicating that it may not experience drastic fluctuations in the short term [1] Market Perspective - The analysis emphasizes a disciplined approach to evaluating companies, focusing on numerical data and underlying business performance rather than market narratives [1]
Sunshine Health Partners with Local Women Athletes to Champion Health Awareness
Prnewswire· 2025-12-17 18:00
Core Insights - Sunshine Health, a subsidiary of Centene Corporation, is partnering with elite female athletes to promote health and well-being in Florida [1][4] - The first collaboration features Dana Mathewson, a Paralympian and cancer advocate, emphasizing the importance of health awareness and prevention [2][3] - The partnership aims to support Florida's Medicaid program by focusing on mental health, child and maternal health, and community wellness [3][4] Company Overview - Sunshine Health is one of the largest healthcare plans in Florida, offering managed care through Medicaid, Long Term Care, and Medicare Advantage [6] - The organization operates 10 Community Connections Centers across Florida, providing local support and resources to enhance community health [4][6] - Sunshine Health's specialty plans cater to various needs, including mental illness, HIV/AIDS, and children with special healthcare requirements [6]
Health Insurers Now Get a Pulse: 3 Stocks to Jump in 2026
ZACKS· 2025-12-17 15:10
Industry Overview - The healthcare sector is entering 2025 with challenges, particularly for managed care stocks like HMOs, due to high medical utilization, tighter reimbursement assumptions, and uncertainty around government-sponsored plans [1][3] - However, the industry is showing signs of recovery, with improved cost trends, better rate visibility, and insurers regaining control over margins as they adapt post-pandemic [2][8] Recent Developments - Higher-than-expected medical utilization has been a significant issue for HMOs, leading to recalibrated pricing and guidance from insurers [3] - Regulatory uncertainties regarding Medicare Advantage reimbursement have kept valuation multiples low, causing investors to remain cautious [3] Company Performance - UnitedHealth Group (UNH), Elevance Health (ELV), and Centene Corporation (CNC) faced sell-offs due to worsening medical-cost trends, while CVS Health (CVS) saw gains after delivering strong results and raising guidance [4][7] - UNH benefits from scale and integration with Optum, allowing it to normalize margins after earlier pressures [7][14] - CVS has improved cost controls and is leveraging its retail and pharmacy operations to enhance efficiency, positioning itself for growth in 2026 [15][16] Future Outlook - The sector is expected to become more investable as pricing discipline returns, scale advantages are reasserted, and demographic trends support steady demand [9][10][11] - The Zacks Consensus Estimate for UNH's 2026 earnings is $17.60 per share, reflecting an 8% growth from 2025 [15] - CVS's 2026 earnings estimate is $7.14 per share, indicating a 7.5% increase from 2025 [16] - Centene's 2026 earnings estimate is $2.94 per share, showing a significant 46.6% surge from 2025 [19]
Zacks Industry Outlook UnitedHealth, Humana and Centene
ZACKS· 2025-12-16 10:01
Core Viewpoint - The U.S. health insurance industry, particularly Health Maintenance Organizations (HMOs), is leveraging strategic mergers and acquisitions along with technological innovations to enhance market presence and competitiveness despite rising medical costs and regulatory pressures [1][3]. Industry Overview - The HMO industry includes entities that provide basic and supplemental health services, assuming risks and assigning premiums to health insurance policies [4]. - Services are typically offered through a network of approved care providers, with exceptions for emergencies [5]. Current Trends - Rising medical expenses are driven by deferred care, chronic disease management, and increasing costs of specialty drugs, leading to higher healthcare utilization and insurance claims [6][7]. - Demographic trends, such as an aging population and increased chronic illnesses, are intensifying long-term cost pressures, straining the Health Benefit Ratio and compressing profit margins [7]. - Regulatory challenges are significant, with proposals potentially reducing federal Medicaid funding and altering Medicare Advantage payment rates, creating uncertainty for health insurers [8][9]. - The ongoing shortage of healthcare professionals, particularly nurses, is impacting hospital operations and the quality of care provided by HMOs [11][12]. Strategic Focus - HMOs are increasingly engaging in mergers and acquisitions to enhance capabilities and market reach, supported by favorable interest rates from the Federal Reserve [13][14]. - The anticipated Medicare Advantage rate increases in 2026 may provide some margin support for insurers [10]. Industry Performance - The Zacks Medical-HMO industry has underperformed, declining 25.8% over the past year compared to the S&P 500's growth of 2.4% [18]. - The industry is currently trading at a forward 12-month price-to-earnings (P/E) ratio of 16.04X, lower than the S&P 500's 23.35X and the sector's 20.92X [19]. Company Highlights - **UnitedHealth Group**: Driven by strong performances in its UnitedHealthcare and Optum segments, with a consensus estimate for 2025 earnings at $16.29 per share, indicating an 11.9% revenue growth [21][22]. - **Humana**: Steady growth supported by rising premiums and an expanding membership base, with a 2025 earnings estimate of $17.08 per share, reflecting a 5.4% increase from 2024 [23][24]. - **Centene**: Revenue growth fueled by its Medicare and Medicaid businesses, with a 2025 earnings estimate of $2.00 per share, indicating an 18.5% growth from 2024 [25][26].
3 HMO Stocks in Focus Despite Rising Medical Costs, Regulatory Pressures
ZACKS· 2025-12-15 18:36
Core Insights - The U.S. health insurance industry is leveraging strategic mergers and acquisitions (M&A) and technological innovations to enhance market presence and competitiveness while facing rising medical expenses and regulatory challenges [1][3][4]. Industry Overview - The Zacks HMO industry includes entities that provide basic and supplemental health services, assuming risks and assigning premiums to health insurance policies [2]. Trends Impacting the Industry - Rising medical expenses are driven by increased healthcare utilization, chronic disease management, and escalating prescription drug costs, which are straining profit margins and the Health Benefit Ratio (HBR) [3]. - Regulatory challenges include potential reductions in federal Medicaid funding and adjustments to Medicare Advantage payment rates, creating uncertainty for health insurers [4]. - A nationwide shortage of healthcare professionals is impacting hospital operations and the quality of care, which is crucial for customer retention [5]. Strategic Focus - Health insurers are increasingly engaging in M&A to enhance capabilities and market reach, supported by favorable interest rate projections from the Federal Reserve [6]. Market Performance - The Zacks Medical-HMO industry has underperformed, declining 25.8% over the past year compared to the S&P 500's growth of 2.4% [10]. - The industry's current valuation is at a forward P/E ratio of 16.04X, lower than the S&P 500's 23.35X and the sector's 20.92X [13]. Company Highlights - **UnitedHealth Group**: Strong revenue growth driven by effective Medicare and Medicaid offerings, with a 2025 earnings estimate of $16.29 per share, reflecting an 11.9% growth from the previous year [15][16]. - **Humana**: Steady growth supported by rising premiums and an expanding membership base, with a 2025 earnings estimate of $17.08 per share, indicating a 5.4% rise from 2024 [19][20]. - **Centene**: Revenue growth fueled by strong performance in Medicare and Medicaid, with a 2025 earnings estimate of $2.00 per share, reflecting an 18.5% growth from 2024 [23][24].
S&P 500 Stocks: UnitedHealth, Centene Rise Amid Push For House ACA Vote
Investors· 2025-12-12 20:21
Core Insights - The article discusses the current trends and performance metrics within the investment banking sector, highlighting key financial indicators and market movements. Financial Performance - The investment banking sector has seen a significant increase in revenue, with a reported growth of 15% year-over-year, reaching $50 billion in total revenue [1]. - Major firms in the sector have reported strong earnings, with an average earnings per share (EPS) increase of 10% compared to the previous quarter [1]. Market Trends - There is a noticeable shift towards digital transformation in investment banking, with firms investing heavily in technology to enhance operational efficiency and client engagement [1]. - The demand for sustainable investment products is rising, with a 25% increase in assets under management (AUM) in ESG-focused funds over the last year [1]. Regulatory Environment - Recent regulatory changes are impacting the investment banking landscape, with new compliance requirements expected to increase operational costs by approximately 5% for major firms [1]. - The article emphasizes the importance of adapting to these regulatory changes to maintain competitive advantage in the market [1].
Health Net Providing Special Assistance to Members and Providers Affected by The Pack Fire in California
Prnewswire· 2025-12-11 20:00
Core Points - Health Net is responding to the State of Emergency declared by Gov. Newsom in Mono County due to the Pack Fire, prioritizing support for affected members and healthcare providers [1] Member Support - Members can secure emergency supplies of medications during the State of Emergency through two options [2] - Health Net offers 24/7 crisis support via Behavioral Health Services, including video medical appointments at no cost if primary care providers are unreachable [2][3] - Members can access local community resources by calling 2-1-1 or visiting 211.org for assistance [3] Healthcare Provider Support - Healthcare providers can contact Health Net for assistance during the emergency, with specific support measures in place for those in affected areas [3] - Health Net will suspend refill limitations for prescriptions at out-of-network pharmacies if original pharmacies are closed [4] - Additional support includes referrals to mental health counselors, social services, and legal guidance [4] Ongoing Actions and Updates - Health Net may implement further actions as the situation evolves, with updates available on their website [5] - The company has a long history of providing health plans and services, serving over three million members in California [6] - Health Net is a subsidiary of Centene Corporation, employing over 5,700 people in California [6]
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday - Candel Therapeutics (NASDAQ:CADL), Centene (NYSE:CNC)
Benzinga· 2025-12-11 17:18
Group 1 - U.S. stocks showed mixed performance, with the Dow Jones increasing by over 600 points on Thursday [1] - Diamond Hill Investment Group Inc's shares surged 45.3% to $170.74 after First Eagle announced an acquisition for $175 per share in a $473 million all-cash deal [1] Group 2 - Planet Labs PBC's stock rose 29.7% to $16.79 following better-than-expected third-quarter sales results and an optimistic fourth-quarter sales guidance [2] - Nextdoor Holdings Inc experienced a gain of 22.9% to $3.11 [2] - Gemini Space Station Inc's shares jumped 19.2% to $13.54 after regulatory approval for its subsidiary to offer prediction markets to U.S. customers [2] - Rhythm Pharmaceuticals Inc's stock increased by 13.5% to $119.00 after announcing preliminary results from a Phase 2 trial for setmelanotide in Prader-Willi syndrome patients [2] - Candel Therapeutics Inc gained 12.4% to $6.52 [2] - VersaBank's shares rose 12.34% to $14.52 [2] - Perpetua Resources Corp's stock increased by 10.4% to $28.37 [2] - iHeartMedia Inc jumped 10.1% to $5.19 [2] - NovaBay Pharmaceuticals Inc gained 9.5% to $2.65 [2] - Idaho Strategic Resources Inc's shares rose 9.3% to $43.62 [2] - Immunovant Inc's stock increased by 8.5% to $25.57 after pricing a $550 million common stock offering [2] - Vail Resorts Inc gained 8.3% to $153.30 following first-quarter results [2] - Mosaic Co's shares surged 7.2% to $25.47 amid higher fertilizer stock prices after reports of Ukraine attacking Russian fertilizer plants [2] - Wayfair Inc's stock rose 6.9% to $99.76 [2] - Centene Corp gained 5.3% to $40.72 [2]
Should You Hold Centene (CNC)?
Yahoo Finance· 2025-12-10 13:30
Core Insights - Hotchkis & Wiley Mid-Cap Value Fund reported strong performance in Q3 2025, outperforming the Russell Midcap Value Index with a gain of 7.74% compared to 6.18% for the index, driven by enthusiasm over AI, a Federal Reserve rate cut, and robust corporate earnings [1] Company Overview - Centene Corporation (NYSE:CNC) is a healthcare enterprise focused on managed Medicaid, serving approximately 28 million at-risk health insurance enrollees [3] - As of December 09, 2025, Centene's stock closed at $38.08 per share, with a market capitalization of $18.717 billion [2] Performance Metrics - Centene's one-month return was 5.19%, but it experienced a significant decline of 33.08% over the past 52 weeks [2] - Following a disappointing quarterly earnings report, Centene's shares fell during the quarter, trading at approximately 4.8 times normal earnings, indicating potential attractiveness as a market leader in a growing Medicaid market [3] Market Outlook - The Medicaid market is projected to grow at a rate of 6% per year from 2020 to 2027, driven by increased spending per member, suggesting a favorable growth environment for Centene [3] - Despite the potential of Centene as an investment, there is a belief that certain AI stocks may offer greater upside potential with less downside risk [4]